Pirbright generates first pig flu antibodies that could improve human treatments and guide flu vaccine selection
Posted: 4 March, 2021
The Pirbright Institute has generated the first pig antibodies against swine influenza (flu) that protect against infection and recognise the same parts of the flu virus as human antibodies. This indicates they could be used to develop and assess human antibody therapies and their delivery methods. The pig antibodies also have the potential to improve how flu virus evolution is monitored and inform decisions about annual flu vaccine selection.